查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1844096

乳癌诊断市场按技术、产品、生物标记、样本类型和最终用户划分－2025-2032年全球预测

Breast Cancer Diagnostics Market by Technology, Product, Biomarker, Sample Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，乳癌诊断市场规模将达到 130.6 亿美元，复合年增长率为 8.02%。

主要市场统计数据
基准年 2024 70.4亿美元
预计年份：2025年 76亿美元
预测年份：2032年 130.6亿美元
复合年增长率 (%) 8.02%

简明扼要地介绍不断发展的乳癌诊断格局，重点在于临床效用和营运转型之间的交集。

乳癌诊断正经历快速变革时期，主要得益于采样技术、组织分析、影像技术和分子谱分析技术的同步发展。新的工具正在重塑从初步筛检到最终诊断和治疗方法分层的临床流程，而放射科、病理科和分子实验室之间的多学科合作对于提供精准医疗服务也变得日益重要。更丰富的资料流，包括数位乳房断层合成影像、用于演算法分析的数位化免疫组化切片以及来自新一代定序的基因组特征，正在增强临床决策能力。

在此背景下，相关人员必须协调营运限制与不断发展的医疗标准。不同终端使用者（癌症研究中心、诊断实验室、医院和专科诊所）的采纳动态各不相同，并受到耗材、仪器、软体和服务等产品细分的影响。检体类型（血液、血清和组织）的考量持续影响工作流程设计和检体物流。总而言之，诊断领域需要一项综合策略规划，以平衡临床效用、工作流程效率和永续的报销管道。

影像、组织取样、组织病理学自动化和分子谱分析的进展如何系统性地重新定义诊断路径和临床工作流程

多项变革正在改变乳癌的检测、分类和监测方式。首先，影像技术正从类比技术向数位转型，数位乳房断层合成和先进的乳房X光乳房X光摄影与磁振造影（MRI）和超音波相结合，以增强病灶的定性和分诊能力。这些影像技术越来越多地与计算工具相结合，以辅助放射科医生的解读并确定切片检查的优先顺序。其次，随着穿刺和手术技术的不断改进，切片检查方法也日趋多样化，旨在最大限度地保留组织，同时实现全面的后续检测，从而影响实验室的工作流程和耗材需求。

同时，组织病理学正随着免疫组织化学和自动化染色系统的日益普及而不断发展，这些技术提高了检测通量和可重复性。萤光杂合反应、 PCR变体和新一代测序（包括靶向测序和全基因组测序）提供了详细的生物标誌物信息，从而指导治疗决策。与这些技术变革相辅相成的是以数据分析软体和咨询为核心的新型服务模式，这些模式支持结果解读、品管以及与电子健康记录的整合。总而言之，这些趋势正在重塑整个诊断生态系统的采购重点、临床路径和伙伴关係。

2025年美国关税环境对诊断供应链、筹资策略、临床取得先进检测的实际影响

美国在2025年前实施的关税和贸易措施，已对诊断设备和试剂的供应链造成了实际的摩擦。进口关税及相关合规要求推高了某些设备和耗材的成本，影响了采购週期，并促使一些实验室和医院重新评估其供应商多元化策略。为此，采购团队越来越重视本地库存缓衝和能够缓解关税波动的合约条款，而製造商则在评估本土生产和近岸外包，以降低跨境关税带来的影响。

由于这种转变，商业策略正在调整，以维持医疗服务的连续性，并确保患者能够获得定序仪、成像系统和专用染色试剂等关键检测工具。製造商和经销商正在重新谈判经销商协议，并探索联合承包模式以稳定供应。对于临床领导者而言，关税环境凸显了供应链弹性规划和基于情境的预算编制的重要性，这些规划和预算编制需考虑监管和贸易主导的成本，同时确保诊断品质和患者能够及时获得检测。

从技术架构、产品系列、生物标记、样本类型和最终用户需求等方面获取可操作的细分洞察，以指南优先排序。

了解市场区隔对于使产品开发和商业化与临床需求和购买行为保持一致至关重要。技术细分揭示了切片检查、组织病理学、影像学和分子诊断领域截然不同的动态。切片检查需求因穿刺和手术方法而异，这两种方法都会影响样本完整性和下游检测的适用性。组织病理学工作流程因免疫组织化学和染色系统而异，每种方法都需要客製化的试剂组合和自动化选项。数位乳房断层合成、乳房X光摄影、MRI和超音波等影像技术在筛检和诊断管道中定位日益明确，包括资本投资和培训方面的影响。分子诊断包括FISH、基于PCR的方法和次世代定序仪，其中靶向NGS和全基因组定序对数据分析和实验室基础设施提出了不同的要求。基于PCR的方法在灵敏度和通量方面又可分为数位PCR和即时PCR。

产品细分进一步细化了耗材、仪器、软体和服务等方面的责任。试剂和玻片等耗材对经常性收入和物流较为敏感，而从切片检查设备和组织病理学仪器到成像系统和定序仪等仪器则需要长期的服务和升级策略。咨询、维护和数据分析平台等软体和服务对于从复杂数据集中提取临床价值至关重要。生物标记细分涵盖 BRCA、ER/PR、HER2 和 Ki-67 等，有助于确定检测方法开发的优先顺序，并支持伴随诊断的临床效用。血液、血清和组织等检体类型会影响分析前工作流程、稳定性方案以及适当的分子和影像方法的选择。最后，针对癌症研究中心、诊断实验室、医院和专科诊所的终端用户细分，凸显了从研究级检测到高性能临床诊断等各种适用解决方案的需求。

美洲、欧洲、中东和非洲以及亚太地区之间的区域需求和应用差异将决定临床应用和商业策略。

区域动态正在影响全球的技术应用、监管管道和报销机制。在美洲，强大的临床研究网络和医院系统支援先进影像和分子诊断平台的快速普及，而供应链因素和政策变化则影响采购行为。欧洲、中东和非洲的情况则截然不同。西欧市场通常在整合数位病理和综合生物标记检测方面处于领先地位，但该地区的新兴市场面临基础设施和准入方面的限制，因此优先考虑成本效益高且可靠的诊断方式。监管协调工作和跨境合作正在逐步加快创新从研究到实践的转化速度。

在亚太地区，基础设施的快速发展和对医疗技术的巨额投资正在加速高性能分子检测工具和成像解决方案的普及，尤其註重可扩展性和本地化生产。不同地区的报销机制、劳动力供应以及集中式与分散式检测模式的差异是影响技术应用的关键因素。因此，商业策略必须因地制宜，在标准化的全球价值主张与反映当地临床工作流程和监管要求的客製化实施提案之间取得平衡。

竞争定位、伙伴关係和临床检验如何重新定义乳癌诊断技术和服务领域的领导地位

乳癌诊断领域的竞争格局由传统设备供应商、新兴分子诊断专家和数位医疗参与企业组成。现有企业持续投资于影像系统、切片检查设备和组织病理学仪器的渐进式创新，而新参与企业则专注于小众分子检测、标靶定序平台和软体主导的解读工具。对于那些寻求将硬体功能与分析软体和资讯服务相结合，以提供端到端诊断解决方案的公司而言，策略伙伴关係和共同开发契约正变得越来越普遍。

此外，透过针对性地收购利基技术供应商以及与临床网路建立合作关係来实现整合，正在重塑市场策略。强大的售后服务和培训课程能够使供应商脱颖而出，尤其对于需要持续维护和验证的复杂设备而言更是如此。取得高品质、经过筛选的临床资料集，并透过同行评审的研究和真实世界证据来证明其临床效用，是至关重要的竞争优势。最终，能够整合强大的临床检验、可扩展的生产能力和快速响应的商业支援的公司，将最有希望赢得与医院、实验室和专科诊所的长期合约。

为製造商、临床领导者和支付者提供切实可行、影响深远的建议，以加速临床应用，同时保障营运弹性。

产业领导者应优先考虑兼顾临床影响和营运可扩展性的投资。首先，製造商应加快影像处理平台、实验室仪器和分子分析之间的集成，以建立一个可互通的生态系统，从而简化临床医生的工作流程并减少交接环节。其次，改善服务模式，例如预测性维护、培训和数据主导咨询，可以提高客户维繫并降低机构投资者的整体拥有成本。第三，企业应建构模组化产品套件，使医院和实验室能够在不中断核心临床服务的情况下逐步升级和添加功能。

从临床角度来看，相关人员必须重视检测标准化和跨部门培训，以确保影像学和分子检测结果解读的一致性。供应链多元化和区域库存策略可降低关税和贸易风险，同时保障关键耗材和设备的供应。最后，支付方和医疗系统应儘早参与，制定以金额为准的报销机制，充分认可精准诊断的后续益处，例如减少过度治疗和改善治疗方法匹配。采取这些措施将有助于新技术的持续应用，并最大限度地发挥其临床效用。

一个稳健的混合方法研究框架，结合了初步临床见解、监管分析和工作流程图谱，以支援策略诊断情报。

本研究整合了同行评审文献、监管指导文件、临床实验室註册资讯以及对临床实验室技术人员、病理学家、放射科医生和采购负责人的访谈，从而对诊断现状进行了全面的分析。研究采用定量数据与定性见解相结合的方式，确保对技术成熟度、临床效用和商业性可行性进行平衡的解读。调查方法着重于绘製切片检查、组织病理学、影像学和分子诊断的工作流程图，并考察了耗材、仪器和软体服务的产品生命週期，以识别瓶颈和整合机会，并了解售后市场动态。

透过对技术规格、监管许可和设备标籤进行交叉验证，以及专家检验会议以确认临床有效性，确保了数据品质。区域分析纳入了美洲、欧洲、中东和非洲以及亚太地区的法律规范和报销模式，以反映不同的实施场景。研究结果尽可能辅以用例和实际案例，以确保策略建议具有实际操作意义。

对融合诊断模式的策略概述以及将创新转化为临床影响所需的营运前提条件

总之，乳癌诊断领域正朝着影像学、组织学分析和分子谱分析的紧密整合方向发展，并辅以软体和服务，实现数据驱动的临床决策。这些整合模式为提高诊断准确性、实现个人化治疗选择和简化治疗流程创造了机会，但也需要完善的营运规划和跨临床专科的协作模式。投资于互通性、临床检验和区域性商业性模式的相关人员将更有能力将技术前景转化为可衡量的患者获益。

展望未来，稳健的供应链、灵活的监管策略以及对支付方的显着价值将是持续推广的关键推动因素。透过将产品蓝图与实际临床工作流程相契合，并儘早与终端用户和支付方进行沟通，诊断创新者和医疗系统可以加速高价值技术的应用，同时确保及时、准确的乳癌诊断服务的公平获取。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 利用机器学习演算法增强数位乳房摄影中的病灶侦测
  • 扩大循环肿瘤DNA液态生物检体检测规模，用于早期乳癌监测
  • 整合以患者为中心的行动医疗平台，用于追踪治疗依从性
  • 监管部门核准推进HER2和PIK3CA标靶治疗伴随诊断
  • 实施结合遗传和影像生物标记的风险分层模型
  • 开发三维自动化乳房超音波系统以提高緻密组织的检出率
  • 利用远距离诊断和远端医疗就诊的去中心化临床检测的出现
  • 扩大支付方奖励和乳癌预防筛检的报销框架

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章乳癌诊断市场（依技术划分）

  • 切片检查
    • 针刺切片
    • 手术切片检查
  • 组织病理学
    • 免疫组织化学
    • 染色系统
  • 影像
    • 数位乳房断层合成
    • 乳房X光检查
    • MRI
    • 超音波
  • 分子诊断
    • FISH
    • NGS
      • 标靶NGS
      • 全基因组序列分析
    • 基于PCR的
      • 数位PCR
      • 即时PCR

第九章乳癌诊断产品市场

  • 消耗品
    • 试剂和套件
    • 玻片和染色试剂
  • 装置
    • 切片检查装置
    • 组织病理学设备
    • 影像系统
    • 序列器
  • 软体和服务
    • 咨询和维护
    • 数据分析软体

第十章乳癌诊断市场（依生物标记划分）

  • BRCA
  • ER/PR
  • HER2
  • Ki-67

第十一章 依样本类型分類的乳癌诊断市场

  • 血
  • 血清
  • 组织

第十二章乳癌诊断市场（依最终用户划分）

  • 癌症研究中心
  • 诊断实验室
  • 医院
  • 专科诊所

第十三章乳癌诊断市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章乳癌诊断市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国乳癌诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • F. Hoffmann-La Roche Ltd.
    • GE HealthCare Technologies GmbH
    • Siemens Healthineers AG
    • Hologic, Inc.
    • Koninklijke Philips NV
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories
    • QIAGEN NV
    • Illumina, Inc.
    • Becton, Dickinson and Company
Product Code: MRR-A26E0E57405A

The Breast Cancer Diagnostics Market is projected to grow by USD 13.06 billion at a CAGR of 8.02% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.04 billion
Estimated Year [2025] USD 7.60 billion
Forecast Year [2032] USD 13.06 billion
CAGR (%) 8.02%

A concise orientation to the evolving breast cancer diagnostics landscape highlighting crossroads between clinical utility and operational transformation

Breast cancer diagnostics are undergoing a period of rapid transformation driven by parallel advances in sampling techniques, tissue analytics, imaging technologies, and molecular profiling. Emerging tools are reshaping clinical pathways from initial screening through definitive diagnosis and therapeutic stratification, while multidisciplinary collaboration between radiology, pathology, and molecular laboratories is increasingly essential to deliver precision care. Clinical decision-making is being augmented by richer data streams, including digital breast tomosynthesis images, immunohistochemistry slides digitized for algorithmic review, and genomic signatures from next-generation sequencing, all of which create both opportunity and complexity for providers and industry.

Against this backdrop, stakeholders must reconcile operational constraints with evolving standards of care. Adoption dynamics differ across end users such as cancer research centers, diagnostic laboratories, hospitals, and specialized clinics, and they are influenced by product segmentation spanning consumables, instruments, and software and services. Sample type considerations, whether blood, serum, or tissue, will continue to dictate workflow design and specimen logistics. In sum, the diagnostic landscape requires integrated strategic planning that balances clinical utility, workflow efficiency, and sustainable reimbursement pathways.

How advances in imaging, tissue sampling, histopathology automation, and molecular profiling are systematically redefining diagnostic pathways and clinical workflows

Several transformative shifts are changing how breast cancer is detected, classified, and monitored. First, imaging is moving from analogue to digital-first ecosystems, where digital breast tomosynthesis and advanced mammography are complemented by MRI and ultrasound to enhance lesion characterization and triage. These imaging modalities are increasingly integrated with computational tools that augment radiologist interpretation and prioritize cases for biopsy. Second, biopsy approaches are diversifying as needle and surgical techniques are refined to maximize tissue preservation while enabling comprehensive downstream testing, which in turn affects laboratory workflows and consumable demand.

Meanwhile, histopathology is evolving through greater adoption of immunohistochemistry and automated staining systems that increase throughput and reproducibility. Molecular diagnostics are also rising in clinical prominence; fluorescence in situ hybridization, PCR variants, and next-generation sequencing, including targeted panels and whole genome approaches, are delivering granular biomarker insights that drive therapeutic decisions. Complementing these technological shifts are new service models around data analysis software and consulting that support interpretation, quality control, and integration with electronic medical records. Collectively, these trends are reshaping procurement priorities, clinical pathways, and partnerships across the diagnostic ecosystem.

Practical implications of the United States tariff environment in 2025 on diagnostic supply chains, procurement strategies, and clinical access to advanced testing

Tariff policies and trade measures in the United States for 2025 have introduced practical friction into the supply chains that underpin diagnostic device and reagent availability. Import duties and related compliance requirements have elevated the cost of certain instruments and consumables, affecting procurement timelines and prompting some laboratories and hospitals to reassess supplier diversification strategies. In response, procurement teams are increasingly emphasizing localized inventory buffers and contractual clauses that mitigate tariff volatility, while manufacturers are evaluating onshore production and nearshoring to reduce exposure to cross-border tariff impacts.

As a result of these shifts, commercial strategies are adapting to preserve continuity of care and maintain access to critical testing modalities such as sequencers, imaging systems, and specialized staining reagents. Manufacturers and distributors are negotiating revised reseller agreements and exploring collaborative consignment models to stabilize supply. For clinical leaders, the tariff environment underscores the importance of supply chain resilience planning and scenario-based budgeting that account for regulatory and trade-driven costs, without compromising diagnostic quality or patient access to timely testing.

Actionable segmentation insights across technology architectures, product portfolios, biomarkers, sample types, and end-user demands to guide prioritization

Understanding market segmentation is essential to align product development and commercialization with clinical needs and purchasing behavior. Technology segmentation reveals distinct dynamics across biopsy, histopathology, imaging, and molecular diagnostics. Biopsy demand is differentiated by needle and surgical approaches, each influencing sample integrity and downstream assay compatibility. Histopathology workflows are bifurcated by immunohistochemistry and staining systems that require tailored reagent portfolios and automation options. Imaging modalities including digital breast tomosynthesis, mammography, MRI, and ultrasound are being positioned differently across screening and diagnostic pathways, with implications for capital investment and training. Molecular diagnostics encompass FISH, PCR-based methods, and next-generation sequencing, where targeted NGS and whole genome sequencing create divergent demands for data analysis and laboratory infrastructure, and PCR-based approaches split between digital PCR and real-time PCR in terms of sensitivity and throughput.

Product segmentation further delineates responsibilities across consumables, instruments, and software and services. Consumables such as reagents and slides have recurring revenue profiles and logistics sensitivities, whereas instruments-ranging from biopsy devices and histopathology instruments to imaging systems and sequencers-require long-term service and upgrade strategies. Software and services, including consulting, maintenance, and data analysis platforms, are increasingly important to extract clinical value from complex datasets. Biomarker segmentation, spanning BRCA, ER/PR, HER2, and Ki-67, dictates assay development priorities and informs clinical utility claims for companion diagnostics. Sample type considerations-blood, serum, and tissue-impact pre-analytical workflows, stability protocols, and the selection of appropriate molecular or imaging approaches. Finally, end user segmentation, covering cancer research centers, diagnostic laboratories, hospitals, and specialized clinics, highlights the need for adaptable solutions that can scale from research-grade assays to high-throughput clinical diagnostics.

Regional imperatives and adoption differentials across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine clinical adoption and commercial strategy

Regional dynamics shape technology adoption, regulatory pathways, and reimbursement practices across the globe. In the Americas, strong clinical research networks and hospital systems are supporting rapid uptake of advanced imaging and molecular diagnostic platforms, while supply chain considerations and policy shifts are influencing procurement behavior. Europe, the Middle East & Africa present a heterogeneous picture: Western European markets often lead in integrating digital pathology and comprehensive biomarker testing, while emerging markets in the region face infrastructure and access constraints that prioritize cost-effective and robust diagnostic modalities. Regulatory harmonization efforts and cross-border collaborations are gradually altering the pace at which innovations move from research to practice.

In the Asia-Pacific region, rapid infrastructure development and significant investments in healthcare technology are accelerating adoption of high-throughput molecular tools and imaging solutions, with an emphasis on scalability and localized manufacturing. Across all regions, differences in reimbursement frameworks, workforce capacity, and centralized versus decentralized laboratory models are the primary determinants of technology diffusion. Consequently, commercial strategies must be regionally nuanced, balancing standardized global value propositions with tailored implementations that reflect local clinical workflows and regulatory expectations.

How competitive positioning, partnerships, and clinical validation are redefining leadership in breast cancer diagnostic technologies and service delivery

Competitive dynamics in breast cancer diagnostics are defined by a mix of legacy instrument providers, emerging molecular specialists, and digital health entrants. Incumbent manufacturers continue to invest in incremental innovation for imaging systems, biopsy devices, and histopathology instrumentation, while newer entrants focus on niche molecular assays, targeted sequencing panels, and software-driven interpretation tools. Strategic partnerships and co-development agreements are increasingly common as companies seek to pair hardware capabilities with analytic software and data services to deliver end-to-end diagnostic solutions.

Moreover, consolidation through targeted acquisition of niche technology providers and alliances with clinical networks is reshaping go-to-market strategies. Strong aftermarket services and training programs are differentiating suppliers, especially for complex instruments that require ongoing maintenance and validation. Access to high-quality, curated clinical datasets and the ability to demonstrate clinical utility through peer-reviewed studies and real-world evidence are essential competitive advantages. Ultimately, companies that can integrate robust clinical validation, scalable manufacturing, and responsive commercial support will be best positioned to capture long-term engagement with hospitals, laboratories, and specialized clinics.

Practical, high-impact recommendations for manufacturers, clinical leaders, and payers to accelerate clinical adoption while safeguarding operational resilience

Industry leaders should prioritize investments that align clinical impact with operational scalability. First, manufacturers should accelerate integration between imaging platforms, laboratory instrumentation, and molecular analytics to create interoperable ecosystems that simplify clinician workflows and reduce handoffs. Second, enhancing service models-through predictive maintenance, training, and data-driven consulting-will increase customer retention and lower the total cost of ownership for institutional buyers. Third, companies should build modular product offerings that allow hospitals and laboratories to phase upgrades and add capabilities without disrupting core clinical services.

From a clinical perspective, stakeholders must emphasize assay standardization and cross-disciplinary training to ensure consistent interpretation of imaging and molecular results. Supply chain diversification and localized inventory strategies can mitigate tariff and trade risk while preserving access to critical consumables and instruments. Finally, payers and health systems should be engaged early to define value-based reimbursement pathways that recognize the downstream benefits of precise diagnostics, including reduced overtreatment and improved therapy matching. Taken together, these measures will enable sustainable adoption and maximize the clinical utility of emerging diagnostic innovations.

A robust mixed-methods research framework combining primary clinical insights, regulatory analysis, and workflow mapping to underpin strategic diagnostics intelligence

This research synthesized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and primary interviews with clinical laboratorians, pathologists, radiologists, and procurement leaders to create a holistic diagnostic landscape analysis. Quantitative inputs were triangulated with qualitative insights to ensure balanced interpretation of technology readiness, clinical utility, and commercial feasibility. The methodology placed particular emphasis on workflow mapping across biopsy, histopathology, imaging, and molecular diagnostics to identify bottlenecks and integration opportunities, and it examined product life cycles for consumables, instruments, and software-enabled services to understand aftermarket dynamics.

Data quality was assured through cross-validation of technical specifications, regulatory clearances, and device labeling, coupled with expert validation sessions to confirm clinical relevance. Regional analyses incorporated regulatory frameworks and reimbursement paradigms across the Americas, Europe, Middle East & Africa, and Asia-Pacific to reflect diverse adoption scenarios. Where possible, findings were corroborated with case studies and implementation examples to ground strategic recommendations in operational reality.

A strategic summation of converging diagnostic modalities and the operational prerequisites needed to translate innovation into clinical impact

In conclusion, the breast cancer diagnostics field is moving toward tighter integration of imaging, tissue-based analyses, and molecular profiling, supported by software and services that enable data-driven clinical decisions. These converging modalities are creating opportunities to refine diagnostic accuracy, personalize treatment selection, and streamline care pathways, but they also necessitate robust operational planning and collaborative models across clinical specialties. Stakeholders that invest in interoperability, clinical validation, and regionally adapted commercial approaches will be best positioned to translate technological promise into measurable patient benefit.

Looking forward, resilience in supply chains, agility in regulatory strategy, and demonstrable value to payers will be critical enablers of sustainable adoption. By aligning product roadmaps with real-world clinical workflows and by engaging early with end users and payers, diagnostic innovators and health systems can accelerate the adoption of high-value technologies while maintaining equitable access to timely and accurate breast cancer diagnosis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of machine learning algorithms for enhanced lesion detection in digital mammography
  • 5.2. Expansion of circulating tumor DNA liquid biopsy tests for early breast cancer monitoring
  • 5.3. Integration of patient-centric mobile health platforms for treatment adherence tracking
  • 5.4. Regulatory approvals driving companion diagnostics for targeted HER2 and PIK3CA therapies
  • 5.5. Implementation of risk stratification models combining genetics and imaging biomarkers
  • 5.6. Development of 3D automated breast ultrasound systems to improve detection rates in dense tissue
  • 5.7. Emergence of decentralized clinical trials leveraging remote diagnostics and telehealth visits
  • 5.8. Growing payer incentives and reimbursement frameworks for preventive breast cancer screening

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Breast Cancer Diagnostics Market, by Technology

  • 8.1. Biopsy
    • 8.1.1. Needle Biopsy
    • 8.1.2. Surgical Biopsy
  • 8.2. Histopathology
    • 8.2.1. Immunohistochemistry
    • 8.2.2. Staining Systems
  • 8.3. Imaging
    • 8.3.1. Digital Breast Tomosynthesis
    • 8.3.2. Mammography
    • 8.3.3. MRI
    • 8.3.4. Ultrasound
  • 8.4. Molecular Diagnostics
    • 8.4.1. FISH
    • 8.4.2. NGS
      • 8.4.2.1. Targeted NGS
      • 8.4.2.2. Whole Genome Sequencing
    • 8.4.3. PCR-Based
      • 8.4.3.1. Digital PCR
      • 8.4.3.2. Real-Time PCR

9. Breast Cancer Diagnostics Market, by Product

  • 9.1. Consumables
    • 9.1.1. Reagents And Kits
    • 9.1.2. Slides And Staining Reagents
  • 9.2. Instruments
    • 9.2.1. Biopsy Devices
    • 9.2.2. Histopathology Instruments
    • 9.2.3. Imaging Systems
    • 9.2.4. Sequencers
  • 9.3. Software And Services
    • 9.3.1. Consulting And Maintenance
    • 9.3.2. Data Analysis Software

10. Breast Cancer Diagnostics Market, by Biomarker

  • 10.1. BRCA
  • 10.2. ER/PR
  • 10.3. HER2
  • 10.4. Ki-67

11. Breast Cancer Diagnostics Market, by Sample Type

  • 11.1. Blood
  • 11.2. Serum
  • 11.3. Tissue

12. Breast Cancer Diagnostics Market, by End User

  • 12.1. Cancer Research Centers
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals
  • 12.4. Specialized Clinics

13. Breast Cancer Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Breast Cancer Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Breast Cancer Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd.
    • 16.3.2. GE HealthCare Technologies GmbH
    • 16.3.3. Siemens Healthineers AG
    • 16.3.4. Hologic, Inc.
    • 16.3.5. Koninklijke Philips N.V.
    • 16.3.6. Thermo Fisher Scientific Inc.
    • 16.3.7. Abbott Laboratories
    • 16.3.8. QIAGEN N.V.
    • 16.3.9. Illumina, Inc.
    • 16.3.10. Becton, Dickinson and Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BREAST CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BREAST CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BREAST CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NEEDLE BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NEEDLE BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NEEDLE BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NEEDLE BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NEEDLE BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NEEDLE BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STAINING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STAINING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STAINING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STAINING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STAINING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STAINING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL BREAST TOMOSYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL BREAST TOMOSYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL BREAST TOMOSYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL BREAST TOMOSYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL BREAST TOMOSYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL BREAST TOMOSYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY FISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY FISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY FISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY FISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY FISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY FISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED NGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED NGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED NGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED NGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED NGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED NGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SLIDES AND STAINING REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SLIDES AND STAINING REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SLIDES AND STAINING REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SLIDES AND STAINING REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SLIDES AND STAINING REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SLIDES AND STAINING REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSULTING AND MAINTENANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSULTING AND MAINTENANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSULTING AND MAINTENANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSULTING AND MAINTENANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSULTING AND MAINTENANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSULTING AND MAINTENANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER/PR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER/PR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER/PR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER/PR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER/PR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER/PR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER2, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER2, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER2, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER2, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER2, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER2, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KI-67, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KI-67, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KI-67, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KI-67, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KI-67, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KI-67, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2025-203